Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

William Catalona

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Prostate

Physiology

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
55
Roehl, Kimberly
35
Loeb, Stacy
34
Smith, Deborah
24
Han, Misop
23
Antenor, Jo Ann
14
Humphrey, Peter
14
Suarez, Brian
13
Keetch, DW
12
D'Amico, Anthony
12
Carvalhal, Gustavo
11
Andriole, Gerald
10
Hudson, MA
10
Witte, John
9
Ramos, Christian
9
Scardino, Peter

Sign-in to see all Coauthors

Publications

TOP 3
Catalona William J
Editorial comment.
Loeb Stacy; Helfand Brian T; Kan Donghui; Isaacs William B; Catalona William J
Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness?
Pal Prodipto; Xi Huifeng; Guha Saurav; Sun Guangyun; Helfand Brian T; Meeks Joshua J; Suarez Brian K; Catalona William J; Deka Ranjan
Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of William Catalona (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Catalona William J
Editorial comment.
The Journal of urology 2009;182(5):2278-9; discussion 2279.
2009: Loeb Stacy; Helfand Brian T; Kan Donghui; Isaacs William B; Catalona William J
Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness?
BJU international 2009;104(9):1200-3.
2009: Pal Prodipto; Xi Huifeng; Guha Saurav; Sun Guangyun; Helfand Brian T; Meeks Joshua J; Suarez Brian K; Catalona William J; Deka Ranjan
Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry.
The Prostate 2009;69(14):1548-56.
2009: Catalona William J
Editorial comment.
Urology 2009;74(3):624-5.
2009: Xu Li; Ding Yongzeng; Catalona William J; Yang Ximing J; Anderson Wayne F; Jovanovic Borko; Wellman Kenji; Killmer Jaqueline; Huang Xiaoke; Scheidt Karl A; Montgomery R Bruce; Bergan Raymond C
MEK4 function, genistein treatment, and invasion of human prostate cancer cells.
Journal of the National Cancer Institute 2009;101(16):1141-55.
2009: Helfand Brian T; Mongiu Anne K; Kan Donghui; Kim Dae-Yun; Loeb Stacy; Roehl Kimberly A; Meeks Joshua J; Smith Norm D; Catalona William J
Outcomes of radical prostatectomy for patients with clinical stage T1a and T1b disease.
BJU international 2009;104(3):304-9.
2009: Catalona William J
Prostate-cancer screening.
The New England journal of medicine 2009;361(2):202; author reply 204-5.
2009: Helfand Brian T; Loeb Stacy; Meeks Joshua J; Fought Angela J; Kan Donghui; Catalona William J
Pathological outcomes associated with the 17q prostate cancer risk variants.
The Journal of urology 2009;181(6):2502-7.
2009: Meeks Joshua J; Loeb Stacy; Helfand Brian T; Kan Donghui; Smith Norm D; Catalona William J
Characteristics of prostate cancers detected at prostate specific antigen levels less than 2.5 ng/ml.
The Journal of urology 2009;181(6):2515-8; discussion 2518-9.
2009: Zhang Qiang; Helfand Brian T; Jang Thomas L; Zhu Lihua J; Chen Lin; Yang Ximing J; Kozlowski James; Smith Norm; Kundu Shilajit D; Yang Guangyu; Raji Adekunle A; Javonovic Borko; Pins Michael; Lindholm Paul; Guo Yinglu; Catalona William J; Lee Chung
Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(10):3557-67.
2009: Stephan Carsten; Bangma Chris; Vignati Giulio; Bartsch Georg; Lein Michael; Jung Klaus; Philippe Marianne; Semjonow Axel; Catalona William J
20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers.
The International journal of biological markers 2009;24(2):65-9.
2009: Nguyen Paul L; Chen Ming-Hui; Catalona William J; Moul Judd W; Sun Leon; D'Amico Anthony V
Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors.
International journal of radiation oncology, biology, physics 2009;73(3):659-64.
2009: Loeb Stacy; Catalona William J
What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels?
Nature clinical practice. Urology 2009;6(2):68-9.
2009: Loeb Stacy; Gashti Sara N; Catalona William J
Exclusion of inflammation in the differential diagnosis of an elevated prostate-specific antigen (PSA).
Urologic oncology 2009;27(1):64-6.
2008: Loeb Stacy; Catalona William J
Diagnosis and treatment of prostate cancer. Beyond the controversy over whether and whom to screen, the appropriate method of screening is also subject to debate.
Medical economics 2008;85(24):36-41.
2008: Nguyen Paul L; Chen Ming-Hui; Catalona William J; Alexander Brian M; Roehl Kimberly A; Loeb Stacy; D'Amico Anthony V
Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management.
Cancer 2008;113(11):3146-52.
2008: Loeb Stacy; Chan Daniel W; Sokoll Lori; Kan Donghui; Maggiore Jack; Mikolajczyk Stephen D; Mondo Dana M; Griffin Chris R; Catalona William J
Prostate specific antigen assay standardization bias could affect clinical decision making.
The Journal of urology 2008;180(5):1959-62; discussion 1962-3.
2008: Loeb Stacy; Sutherland Douglas E; D'Amico Anthony V; Roehl Kimberly A; Catalona William J
PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
Urology 2008;72(5):1116-20; discussion 1120.
2008: Loeb Stacy; Roehl Kimberly A; Helfand Brian T; Catalona William J
Complications of open radical retropubic prostatectomy in potential candidates for active monitoring.
Urology 2008;72(4):887-91.
2008: Martin Neil E; Chen Ming-Hui; Catalona William J; Loeb Stacy; Roehl Kimberly A; D'Amico Anthony V
The influence of serial prostate-specific antigen (PSA) screening on the PSA velocity at diagnosis.
Cancer 2008;113(4):717-22.
2008: Loeb Stacy; Roehl Kimberly A; Thaxton C Shad; Catalona William J
Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.
Urology 2008;72(1):143-7.
2008: Loeb Stacy; Roehl Kimberly A; Viprakasit Davis P; Catalona William J
Long-term rates of undetectable PSA with initial observation and delayed salvage radiotherapy after radical prostatectomy.
European urology 2008;54(1):88-94.
2008: Helfand Brian T; Loeb Stacy; Cashy John; Meeks Joshua J; Thaxton C Shad; Han Misop; Catalona William J
Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles.
The Journal of urology 2008;179(6):2197-201; discussion 2202.
2008: Eggener Scott E; Yossepowitch Ofer; Roehl Kimberly A; Loeb Stacy; Yu Xiaoying; Catalona William J
Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program.
Urology 2008;71(6):1016-9.
2008: Loeb Stacy; Roehl Kimberly A; Catalona William J; Nadler Robert B
Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?
BJU international 2008;101(7):817-21.
2008: Meeks Joshua J; Thaxton C Shad; Loeb Stacy; Roehl Kimberly A; Helfand Brian T; Catalona William J
Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
The Journal of urology 2008;179(4):1340-3.
2008: Loeb Stacy; Catalona William J
What to do with an abnormal PSA test.
The oncologist 2008;13(3):299-305.
2007: Ding Yongzeng; Xu Li; Jovanovic Borko D; Helenowski Irene B; Kelly David L; Catalona William J; Yang Ximing J; Pins Michael; Bergan Raymond C
The methodology used to measure differential gene expression affects the outcome.
Journal of biomolecular techniques : JBT 2007;18(5):321-30.
2007: Okotie Onisuru T; Roehl Kimberly A; Han Misop; Loeb Stacy; Gashti Sara N; Catalona William J
Characteristics of prostate cancer detected by digital rectal examination only.
Urology 2007;70(6):1117-20.
2007: Loeb Stacy; Roehl Kimberly A; Nadler Robert B; Yu Xiaoying; Catalona William J
Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
The Journal of urology 2007;178(6):2348-52; discussion 2352-3.
2007: Desireddi Naresh V; Roehl Kimberly A; Loeb Stacy; Yu Xiaoying; Griffin Christopher R; Kundu Shilajit K; Han Misop; Catalona William J
Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era.
Urology 2007;70(5):950-5.
2007: Loeb Stacy; Catalona William J
Open radical retropubic prostatectomy.
Urologic oncology 2007;25(6):494-8.
2007: Pal Prodipto; Xi Huifeng; Sun Guangyun; Kaushal Ritesh; Meeks Joshua J; Thaxton C Shad; Guha Saurav; Jin Carol H; Suarez Brian K; Catalona William J; Deka Ranjan
Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin.
Human genetics 2007;122(3-4):251-9.
2007: Griffin Christopher R; Yu Xiaoying; Loeb Stacy; Desireddi Vic N; Han Misop; Graif Theresa; Catalona William J
Pathological features after radical prostatectomy in potential candidates for active monitoring.
The Journal of urology 2007;178(3 Pt 1):860-3; discussion 863.
2007: Kawachi Mark H; Bahnson Robert R; Barry Michael; Carroll Peter R; Carter H Ballentine; Catalona William J; Epstein Jonathan I; Etzioni Ruth B; Hemstreet George P; Howe Richard J; Kopin Jeff D; Lange Paul H; Lilja Hans; Mohler James; Moul Judd; Nadler Robert B; Patterson Stephan; Pollack Alan; Presti Joseph C; Stroup Antoinette M; Urban Donald A; Wake Robert; Wei John T;
Prostate cancer early detection. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(7):714-36.
2007: Loeb Stacy; Catalona William J
Counterpoint: the case for immediate active treatment.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(7):699-702.
2007: Loeb Stacy; Catalona William J
Early versus delayed intervention for prostate cancer: the case for early intervention.
Nature clinical practice. Urology 2007;4(7):348-9.
2007: D'Amico Anthony V; Chen Ming-Hui; Catalona William J; Sun Leon; Roehl Kimberly A; Moul Judd W
Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors.
Cancer 2007;110(1):56-61.
2007: Graif Theresa; Loeb Stacy; Roehl Kimberly A; Gashti Sara N; Griffin Christopher; Yu Xiaoying; Catalona William J
Under diagnosis and over diagnosis of prostate cancer.
The Journal of urology 2007;178(1):88-92.
2007: Loeb Stacy; Smith Norm D; Roehl Kimberly A; Catalona William J
Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer.
Urology 2007;69(6):1170-5.
2007: Sotelo Rene J; Mora K Elias; Pérez L Hermes; Novoa John; Carmona Oswaldo; De Andrade Robert; Borges Rafael E; Parada David; Loeb Stacy; Catalona William J
Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen.
Urology 2007;69(6):1143-6.
2007: Loeb Stacy; Nadler Robert B; Roehl Kimberly A; Antenor Jo Ann V; Catalona William J
Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
The Journal of urology 2007;177(5):1745-8.
2007: Yu Xiaoying; Loeb Stacy; Roehl Kimberly A; Han Misop; Catalona William J
The association between total prostate specific antigen concentration and prostate specific antigen velocity.
The Journal of urology 2007;177(4):1298-302; discussion 1301-2.
2007: Loeb Stacy; Catalona William J
Prostate-specific antigen in clinical practice.
Cancer letters 2007;249(1):30-9.
2007: Loeb Stacy; Roehl Kimberly A; Catalona William J; Nadler Robert B
Prostate specific antigen velocity threshold for predicting prostate cancer in young men.
The Journal of urology 2007;177(3):899-902.
2007: Kundu Shilajit D; Roehl Kimberly A; Yu Xiaoying; Antenor Jo Ann V; Suarez Brian K; Catalona William J
Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
The Journal of urology 2007;177(2):505-9.
2007: Loeb Stacy; Roehl Kimberly A; Yu Xiaoying; Han Misop; Catalona William J
Use of prostate-specific antigen velocity to follow up patients with isolated high-grade prostatic intraepithelial neoplasia on prostate biopsy.
Urology 2007;69(1):108-12.
2007: Loeb Stacy; Yu Xiaoying; Nadler Robert B; Roehl Kimberly A; Han Misop; Hawkins Sheila A; Catalona William J
Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
The Journal of urology 2007;177(1):102-6; discussion 106.
2006: Roehl Kimberly A; Loeb Stacy; Antenor Jo Ann V; Corbin Nicol; Catalona William J
Characteristics of patients with familial versus sporadic prostate cancer.
The Journal of urology 2006;176(6 Pt 1):2438-42; discussion 2442.
2006: Yu Xiaoying; Han Misop; Loeb Stacy; Gashti Sara N; Yeh Joannie T; Roehl Kimberly A; Catalona William J
Comparison of methods for calculating prostate specific antigen velocity.
The Journal of urology 2006;176(6 Pt 1):2427-31; discussion 2431.
2006: D'Amico Anthony V; Hui-Chen Ming; Renshaw Andrew A; Sussman Brenda; Roehl Kimberly A; Catalona William J
Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
The Journal of urology 2006;176(6 Pt 2):S11-5.
2006: Roehl Kimberly A; Eggener Scott E; Loeb Stacy; Smith Norm D; Antenor Jo Ann V; Catalona William J
Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results.
Urologic oncology 2006;24(6):465-71.
2006: Eggener Scott E; Roehl Kimberly A; Yossepowitch Ofer; Catalona William J
Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
The Journal of urology 2006;176(4 Pt 1):1399-403.
2006: Pal Prodipto; Xi Huifeng; Kaushal Ritesh; Sun Guangyun; Jin Carol H; Jin Li; Suarez Brian K; Catalona William J; Deka Ranjan
Variants in the HEPSIN gene are associated with prostate cancer in men of European origin.
Human genetics 2006;120(2):187-92.
2006: Efstathiou Jason A; Chen Ming-Hui; Catalona William J; McLeod David G; Carroll Peter R; Moul Judd W; Roehl Kimberly A; D'Amico Anthony V
Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
Urology 2006;68(2):342-7.
2006: Loeb Stacy; Catalona William J
What is the prognostic impact of positive surgical margins in surgically treated prostate cancer?
Nature clinical practice. Urology 2006;3(8):418-9.
2006: Rodrigues Neesha A; Chen Ming-Hui; Catalona William J; Roehl Kimberly A; Richie Jerome P; D'Amico Anthony V
Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
Cancer 2006;107(3):514-20.
2006: Loeb Stacy; Roehl Kimberly A; Yu Xiaoying; Antenor Jo Ann V; Han Misop; Gashti Sara N; Yang Ximing J; Catalona William J
Lymphovascular invasion in radical prostatectomy specimens: prediction of adverse pathologic features and biochemical progression.
Urology 2006;68(1):99-103.
2006: Catalona William J; Loeb Stacy
Making prostate-specific antigen testing more effective.
Urologic oncology 2006;24(3):177-9.
2006: Punglia Rinaa S; D'Amico Anthony V; Catalona William J; Roehl Kimberly A; Kuntz Karen M
Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level.
Cancer 2006;106(7):1507-13.
2006: Catalona William J; Loeb Stacy; Han Misop
Viewpoint: expanding prostate cancer screening.
Annals of internal medicine 2006;144(6):441-3.
2006: Galper Shira L; Chen Ming-Hui; Catalona William J; Roehl Kimberly A; Richie Jerome P; D'Amico Anthony V
Evidence to support a continued stage migration and decrease in prostate cancer specific mortality.
The Journal of urology 2006;175(3 Pt 1):907-12.
2006: Loeb Stacy; Gonzalez Chris M; Roehl Kimberly A; Han Misop; Antenor Jo Ann V; Yap Ronald L; Catalona William J
Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.
The Journal of urology 2006;175(3 Pt 1):902-6.
2006: Casey Graham; Neville Phillippa J; Liu Xin; Plummer Sarah J; Cicek Mine S; Krumroy Lisa M; Curran Anthony P; McGreevy Michelle R; Catalona William J; Klein Eric A; Witte John S
Podocalyxin variants and risk of prostate cancer and tumor aggressiveness.
Human molecular genetics 2006;15(5):735-41.
2006: Loeb Stacy; Roehl Kimberly A; Antenor Jo Ann V; Catalona William J; Suarez Brian K; Nadler Robert B
Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
Urology 2006;67(2):316-20.
2006: Jang Thomas L; Han Misop; Roehl Kimberly A; Hawkins Sheila A; Catalona William J
More favorable tumor features and progression-free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific effects.
Urology 2006;67(2):343-8.
2006: Ding Y; Xu L; Chen S; Jovanovic B D; Helenowski I B; Kelly D L; Catalona W J; Yang X J; Pins M; Ananthanarayanan V; Bergan R C
Characterization of a method for profiling gene expression in cells recovered from intact human prostate tissue using RNA linear amplification.
Prostate cancer and prostatic diseases 2006;9(4):379-91.
2005: Punglia Rinaa S; Kuntz Karen M; Catalona William J; D'Amico Anthony
Operating characteristics of prostate-specific antigen and verification bias.
JAMA : the journal of the American Medical Association 2005;294(21):2698; author reply 2698-9.
2005: Nadler Robert B; Loeb Stacy; Roehl Kimberly A; Antenor Jo Ann V; Eggener Scott; Catalona William J
Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years.
The Journal of urology 2005;174(6):2154-7, discussion 2157.
2005: Pazona Joseph F; Han Misop; Hawkins Sheila A; Roehl Kimberly A; Catalona William J
Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates.
The Journal of urology 2005;174(4 Pt 1):1282-6.
2005: Catalona William J; Loeb Stacy
The PSA era is not over for prostate cancer.
European urology 2005;48(4):541-5.
2005: Zhu Hui; Roehl Kimberly A; Antenor Jo Ann V; Catalona William J
Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
Urology 2005;66(3):547-51.
2005: D'Amico Anthony V; Chen Ming-Hui; Roehl Kimberly A; Catalona William J
Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):4975-9.
2005: Grubb Robert L; Roehl Kimberly A; Antenor Jo Ann V; Catalona William J
Results of compliance with prostate cancer screening guidelines.
The Journal of urology 2005;174(2):668-72; discussion 672.
2005: Eggener Scott E; Roehl Kimberly A; Catalona William J
Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy.
The Journal of urology 2005;174(2):500-4.
2005: Antenor Jo Ann V; Roehl Kimberly A; Eggener Scott E; Kundu Shilajit D; Han Misop; Catalona William J
Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c disease.
Urology 2005;66(1):156-60.
2005: Krygiel Julie M; Smith Deborah S; Homan Sharon M; Sumner Walton; Nease Robert F; Brownson Ross C; Catalona William J
Intermediate term biochemical progression rates after radical prostatectomy and radiotherapy in patients with screen detected prostate cancer.
The Journal of urology 2005;174(1):126-30.
2005: Eggener Scott E; Roehl Kimberly A; Smith Norm D; Antenor Jo Ann V; Han Misop; Catalona William J
Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
The Journal of urology 2005;173(4):1150-5.
2005: Kundu Shilajit D; Grubb Robert L; Roehl Kimberly A; Antenor Jo Ann V; Han Misop; Catalona William J
Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml.
The Journal of urology 2005;173(4):1116-20.
2005: Gokden Neriman; Roehl Kimberly A; Catalona William J; Humphrey Peter A
High-grade prostatic intraepithelial neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in screening population.
Urology 2005;65(3):538-42.
2005: Catalona William J
Ownership and use of tissue specimens for research.
JAMA : the journal of the American Medical Association 2005;293(11):1325; author reply 1325-6.
2005: Loeb Stacy; Han Misop; Roehl Kimberly A; Antenor Jo Ann V; Catalona William J
Accuracy of prostate weight estimation by digital rectal examination versus transrectal ultrasonography.
The Journal of urology 2005;173(1):63-5.
2005: Suarez B K; Pal P; Jin C H; Kaushal R; Sun G; Jin L; Pasche B; Deka R; Catalona W J
TGFBR1*6A is not associated with prostate cancer in men of European ancestry.
Prostate cancer and prostatic diseases 2005;8(1):50-3.
2004: Kundu Shilajit D; Roehl Kimberly A; Eggener Scott E; Antenor Jo Ann V; Han Misop; Catalona William J
Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies.
The Journal of urology 2004;172(6 Pt 1):2227-31.
2004: Han Misop; Brannigan Robert E; Antenor Jo Ann V; Roehl Kimberly A; Catalona William J
Association of hemospermia with prostate cancer.
The Journal of urology 2004;172(6 Pt 1):2189-92.
2004: Catalona William J
Prostate cancer screening.
BJU international 2004;94(7):964-6.
2004: Kundu Shilajit D; Han Misop; Catalona William J
Should an isolated humeral lesion detected during prostate cancer metastatic survey be biopsied?
The Journal of urology 2004;172(5 Pt 1):1825-6.
2004: Gonzalez Chris M; Roehl Kimberly A; Antenor Joann V; Blunt Lynn W; Han Misop; Catalona William J
Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
Urology 2004;64(4):723-8.
2004: Roehl Kimberly A; Han Misop; Ramos Christian G; Antenor Jo Ann V; Catalona William J
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.
The Journal of urology 2004;172(3):910-4.
2004: D'Amico Anthony V; Chen Ming-Hui; Roehl Kimberly A; Catalona William J
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.
The New England journal of medicine 2004;351(2):125-35.
2004: Ramos Christian G; Roehl Kimberly A; Antenor Jo Ann V; Humphrey Peter A; Catalona William J
Percent carcinoma in prostatectomy specimen is associated with risk of recurrence after radical prostatectomy in patients with pathologically organ confined prostate cancer.
The Journal of urology 2004;172(1):137-40.
2004: Antenor Jo Ann V; Han Misop; Roehl Kimberly A; Nadler Robert B; Catalona William J
Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study.
The Journal of urology 2004;172(1):90-3.
2004: Catalona William J; Bartsch Georg; Rittenhouse Harry G; Evans Cindy L; Linton Harry J; Horninger Wolfgang; Klocker Helmut; Mikolajczyk Stephen D
Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.
The Journal of urology 2004;171(6 Pt 1):2239-44.
2004: Catalona William J
Prostate specific antigen testing.
The Journal of urology 2004;171(6 Pt 1):2233.
2004: Mikolajczyk Stephen D; Catalona William J; Evans Cindy L; Linton Harry J; Millar Lisa S; Marker Kathy M; Katir Diksha; Amirkhan Anna; Rittenhouse Harry G
Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.
Clinical chemistry 2004;50(6):1017-25.
2004: Han Misop; Gann Peter H; Catalona William J
Prostate-specific antigen and screening for prostate cancer.
The Medical clinics of North America 2004;88(2):245-65, ix.
2004: Zhu Hui; Roehl Kimberly A; Antenor Jo Ann V; Catalona William J
Clinical value of longitudinal free-to-total prostate specific antigen ratio slope to diagnosis of prostate cancer.
The Journal of urology 2004;171(2 Pt 1):661-3.
2004: Burmester James K; Suarez Brian K; Lin Jennifer H; Jin Carol H; Miller Raymond D; Zhang Kai-Qi; Salzman Sherry A; Reding Douglas J; Catalona William J
Analysis of candidate genes for prostate cancer.
Human heredity 2004;57(4):172-8.
2004: Cross D; Reding D J; Salzman S A; Zhang K Q; Catalona W J; Burke J; Burmester J K
Expression and initial promoter characterization of PCAN1 in retinal tissue and prostate cell lines.
Medical oncology (Northwood, London, England) 2004;21(2):145-53.
2003: Catalona William J; Bartsch Georg; Rittenhouse Harry G; Evans Cindy L; Linton Harry J; Amirkhan Anna; Horninger Wolfgang; Klocker Helmut; Mikolajczyk Stephen D
Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml.
The Journal of urology 2003;170(6 Pt 1):2181-5.
2003: Witte John S; Suarez Brian K; Thiel Bonnie; Lin Jennifer; Yu Adong; Banerjee Tarit K; Burmester James K; Casey Graham; Catalona William J
Genome-wide scan of brothers: replication and fine mapping of prostate cancer susceptibility and aggressiveness loci.
The Prostate 2003;57(4):298-308.
2003: Punglia Rinaa S; D'Amico Anthony V; Catalona William J; Roehl Kimberly A; Kuntz Karen M
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen.
The New England journal of medicine 2003;349(4):335-42.
2003: Cramer Scott D; Chang Bao-Li; Rao Anuradha; Hawkins Gregory A; Zheng S Lilly; Wade Wendy N; Cooke Roger T; Thomas Leanne N; Bleecker Eugene R; Catalona William J; Sterling David A; Meyers Deborah A; Ohar Jill; Xu Jianfeng
Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels.
Journal of the National Cancer Institute 2003;95(14):1044-53.
2003: Kibel Adam S; Suarez Brian K; Belani Jay; Oh Joe; Webster Raul; Brophy-Ebbers Michele; Guo Chan; Catalona William J; Picus Joel; Goodfellow Paul J
CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma.
Cancer research 2003;63(9):2033-6.
2003: Neville Phillippa J; Conti David V; Krumroy Lisa M; Catalona William J; Suarez Brian K; Witte John S; Casey Graham
Prostate cancer aggressiveness locus on chromosome segment 19q12-q13.1 identified by linkage and allelic imbalance studies.
Genes, chromosomes & cancer 2003;36(4):332-9.
2003: Zhang Kai Qi; Salzman Sherry A; Reding D J; Suarez Brian K; Catalona William J; Burmester James K
Genetics of prostate cancer.
Clinical medicine & research 2003;1(1):21-8.
2003: Catalona William J
Informed consent for prostate-specific antigen screening.
Urology 2003;61(1):17-9.
2002: Casey Graham; Neville Phillippa J; Plummer Sarah J; Xiang Ying; Krumroy Lisa M; Klein Eric A; Catalona William J; Nupponen Nina; Carpten John D; Trent Jeffrey M; Silverman Robert H; Witte John S
RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases.
Nature genetics 2002;32(4):581-3.
2002: Catalona William J; Antenor Jo Ann V; Roehl Kimberly A; Moul Judd W
Screening for prostate cancer in high risk populations.
The Journal of urology 2002;168(5):1980-3; discussion 1983-4.
2002: Krumholtz Jason S; Carvalhal Gustavo F; Ramos Christian G; Smith Deborah S; Thorson Phataraporn; Yan Yan; Humphrey Peter A; Roehl Kimberly A; Catalona William J
Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.
Urology 2002;60(3):469-73; discussion 473-4.
2002: Neville Phillippa J; Conti David V; Paris Pamela L; Levin Howard; Catalona William J; Suarez Brian K; Witte John S; Casey Graham
Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies.
Neoplasia (New York, N.Y.) 2002;4(5):424-31.
2002: Roehl Kimberly A; Antenor Jo Ann V; Catalona William J
Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng./ml. range.
The Journal of urology 2002;168(3):922-5.
2002: Xu Jianfeng; Meyers Deborah A; Sterling David A; Zheng Siqun L; Catalona William J; Cramer Scott D; Bleecker Eugene R; Ohar Jill
Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2002;11(7):664-9.
2002: Roehl Kimberly A; Antenor Jo Ann V; Catalona William J
Serial biopsy results in prostate cancer screening study.
The Journal of urology 2002;167(6):2435-9.
2002: Gann Peter H; Ma Jing; Catalona William J; Stampfer Meir J
Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation.
The Journal of urology 2002;167(6):2427-34.
2002: Smith Deborah S; Krygiel Julie; Nease Robert F; Sumner Walton; Catalona William J
Patient preferences for outcomes associated with surgical management of prostate cancer.
The Journal of urology 2002;167(5):2117-22.
2001: Abdulkadir S A; Carbone J M; Naughton C K; Humphrey P A; Catalona W J; Milbrandt J
Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma.
Human pathology 2001;32(9):935-9.
2001: Suarez B K; Gerhard D S; Lin J; Haberer B; Nguyen L; Kesterson N K; Catalona W J
Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and healthy controls.
Cancer research 2001;61(13):4982-4.
2001: Goddard K A; Witte J S; Suarez B K; Catalona W J; Olson J M
Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4.
American journal of human genetics 2001;68(5):1197-206.
2001: Walsh P C; Marschke P; Catalona W J; Lepor H; Martin S; Myers R P; Steiner M S
Efficacy of first-generation Cavermap to verify location and function of cavernous nerves during radical prostatectomy: a multi-institutional evaluation by experienced surgeons.
Urology 2001;57(3):491-4.
2001: Abdulkadir S A; Qu Z; Garabedian E; Song S K; Peters T J; Svaren J; Carbone J M; Naughton C K; Catalona W J; Ackerman J J; Gordon J I; Humphrey P A; Milbrandt J
Impaired prostate tumorigenesis in Egr1-deficient mice.
Nature medicine 2001;7(1):101-7.
2001: Reding D J; Zhang K Q; Salzman S A; Thomalla J V; Riepe R E; Suarez B K; Catalona W J; Burmester J K
Identification of a gene frequently mutated in prostate tumors.
Medical oncology (Northwood, London, England) 2001;18(3):179-87.
2000: Suarez B K; Lin J; Witte J S; Conti D V; Resnick M I; Klein E A; Burmester J K; Vaske D A; Banerjee T K; Catalona W J
Replication linkage study for prostate cancer susceptibility genes.
The Prostate 2000;45(2):106-14.
2000: Carvalhal G F; Humphrey P A; Thorson P; Yan Y; Ramos C G; Catalona W J
Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy.
Cancer 2000;89(6):1308-14.
2000: Catalona W J; Southwick P C; Slawin K M; Partin A W; Brawer M K; Flanigan R C; Patel A; Richie J P; Walsh P C; Scardino P T; Lange P H; Gasior G H; Loveland K G; Bray K R
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.
Urology 2000;56(2):255-60.
2000: Naughton C K; Miller D C; Mager D E; Ornstein D K; Catalona W J
A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection.
The Journal of urology 2000;164(2):388-92.
2000: Paris P L; Witte J S; Kupelian P A; Levin H; Klein E A; Catalona W J; Casey G
Identification and fine mapping of a region showing a high frequency of allelic imbalance on chromosome 16q23.2 that corresponds to a prostate cancer susceptibility locus.
Cancer research 2000;60(13):3645-9.
2000: Witte J S; Goddard K A; Conti D V; Elston R C; Lin J; Suarez B K; Broman K W; Burmester J K; Weber J L; Catalona W J
Genomewide scan for prostate cancer-aggressiveness loci.
American journal of human genetics 2000;67(1):92-9.
2000: Catalona W J; Ramos C G; Carvalhal G F; Yan Y
Lowering PSA cutoffs to enhance detection of curable prostate cancer.
Urology 2000;55(6):791-5.
2000: Abdulkadir S A; Carvalhal G F; Kaleem Z; Kisiel W; Humphrey P A; Catalona W J; Milbrandt J
Tissue factor expression and angiogenesis in human prostate carcinoma.
Human pathology 2000;31(4):443-7.
2000: Smith D S; Carvalhal G F; Schneider K; Krygiel J; Yan Y; Catalona W J
Quality-of-life outcomes for men with prostate carcinoma detected by screening.
Cancer 2000;88(6):1454-63.
2000: Suarez B K; Lin J; Burmester J K; Broman K W; Weber J L; Banerjee T K; Goddard K A; Witte J S; Elston R C; Catalona W J
A genome screen of multiplex sibships with prostate cancer.
American journal of human genetics 2000;66(3):933-44.
2000: Yan Y; Carvalhal G F; Catalona W J; Young J D
Primary treatment choices for men with clinically localized prostate carcinoma detected by screening.
Cancer 2000;88(5):1122-30.
2000: Catalona W J; Partin A W; Slawin K M; Naughton C K; Brawer M K; Flanigan R C; Richie J P; Patel A; Walsh P C; Scardino P T; Lange P H; deKernion J B; Southwick P C; Loveland K G; Parson R E; Gasior G H
Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.
Urology 2000;55(3):372-6.
2000: Naughton C K; Ornstein D K; Smith D S; Catalona W J
Pain and morbidity of transrectal ultrasound guided prostate biopsy: a prospective randomized trial of 6 versus 12 cores.
The Journal of urology 2000;163(1):168-71.
1999: Partin A W; Catalona W J; Finlay J A; Darte C; Tindall D J; Young C Y; Klee G G; Chan D W; Rittenhouse H G; Wolfert R L; Woodrum D L
Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis.
Urology 1999;54(5):839-45.
1999: Ramos C G; Carvahal G F; Mager D E; Haberer B; Catalona W J
The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
The Journal of urology 1999;162(5):1587-90.
1999: Southwick P C; Catalona W J; Partin A W; Slawin K M; Brawer M K; Flanigan R C; Patel A; Richie J P; Walsh P C; Scardino P T; Lange P H; Gasior G H; Parson R E; Loveland K G
Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
The Journal of urology 1999;162(4):1346-51.
1999: Catalona W J; Ramos C G; Carvalhal G F
Contemporary results of anatomic radical prostatectomy.
CA: a cancer journal for clinicians 1999;49(5):282-96.
1999: Catalona W J; Partin A W; Finlay J A; Chan D W; Rittenhouse H G; Wolfert R L; Woodrum D L
Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model.
Urology 1999;54(2):220-4.
1999: Catalona W J; Carvalhal G F; Mager D E; Smith D S
Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies.
The Journal of urology 1999;162(2):433-8.
1999: Carvalhal G F; Smith D S; Ramos C; Krygiel J; Mager D E; Yan Y; Catalona W J
Correlates of dissatisfaction with treatment in patients with prostate cancer diagnosed through screening.
The Journal of urology 1999;162(1):113-8.
1999: Ramos C G; Carvalhal G F; Smith D S; Mager D E; Catalona W J
Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer.
The Journal of urology 1999;161(5):1525-9.
1999: Ramos C G; Carvalhal G F; Smith D S; Mager D E; Catalona W J
Retrospective comparison of radical retropubic prostatectomy and 125iodine brachytherapy for localized prostate cancer.
The Journal of urology 1999;161(4):1212-5.
1999: Carvalhal G F; Smith D S; Mager D E; Ramos C; Catalona W J
Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less.
The Journal of urology 1999;161(3):835-9.
1998: Catalona W J; Smith D S
Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results.
The Journal of urology 1998;160(6 Pt 2):2428-34.
1998: Naughton C K; Smith D S; Humphrey P A; Catalona W J; Keetch D W
Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study.
Urology 1998;52(5):808-13.
1998: Smith D S; Carvalhal G F; Mager D E; Bullock A D; Catalona W J
Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men.
The Journal of urology 1998;160(5):1734-8.
1998: Catalona W J; Partin A W; Slawin K M; Brawer M K; Flanigan R C; Patel A; Richie J P; deKernion J B; Walsh P C; Scardino P T; Lange P H; Subong E N; Parson R E; Gasior G H; Loveland K G; Southwick P C
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
JAMA : the journal of the American Medical Association 1998;279(19):1542-7.
1998: Arcangeli C G; Humphrey P A; Smith D S; Harmon T J; Shepherd D L; Keetch D W; Catalona W J
Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population.
Urology 1998;51(4):558-64; discussion 564-5.
1998: Ornstein D K; Smith D S; Humphrey P A; Catalona W J
The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer.
The Journal of urology 1998;159(4):1234-7.
1998: Woodrum D L; Brawer M K; Partin A W; Catalona W J; Southwick P C
Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer.
The Journal of urology 1998;159(1):5-12.
1997: Keetch D W; Andriole G L; Ratliff T L; Catalona W J
Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
Urology 1997;50(6):901-5.
1997: Arcangeli C G; Smith D S; Ratliff T L; Catalona W J
Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures.
The Journal of urology 1997;158(6):2182-7.
1997: Catalona W J; Beiser J A; Smith D S
Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies.
The Journal of urology 1997;158(6):2162-7.
1997: Smith D S; Humphrey P A; Catalona W J
The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience.
Cancer 1997;80(9):1852-6.
1997: Smith D S; Bullock A D; Catalona W J
Racial differences in operating characteristics of prostate cancer screening tests.
The Journal of urology 1997;158(5):1861-5; discussion 1865-6.
1997: Herschman J D; Smith D S; Catalona W J
Effect of ejaculation on serum total and free prostate-specific antigen concentrations.
Urology 1997;50(2):239-43.
1997: Ornstein D K; Smith D S; Rao G S; Basler J W; Ratliff T L; Catalona W J
Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers.
The Journal of urology 1997;157(6):2179-82.
1997: Catalona W J; Smith D S; Ornstein D K
Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
JAMA : the journal of the American Medical Association 1997;277(18):1452-5.
1997: Ornstein D K; Rao G S; Smith D S; Ratliff T L; Basler J W; Catalona W J
Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels.
The Journal of urology 1997;157(1):195-8.
1996: Partin A W; Catalona W J; Southwick P C; Subong E N; Gasior G H; Chan D W
Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age.
Urology 1996;48(6A Suppl):55-61.
1996: Smith D S; Catalona W J; Herschman J D
Longitudinal screening for prostate cancer with prostate-specific antigen.
JAMA : the journal of the American Medical Association 1996;276(16):1309-15.
1996: Smith D S; Bullock A D; Catalona W J; Herschman J D
Racial differences in a prostate cancer screening study.
The Journal of urology 1996;156(4):1366-9.
1996: Keetch D W; McMurtry J M; Smith D S; Andriole G L; Catalona W J
Prostate specific antigen density versus prostate specific antigen slope as predictors of prostate cancer in men with initially negative prostatic biopsies.
The Journal of urology 1996;156(2 Pt 1):428-31.
1996: Keetch D W; Humphrey P A; Smith D S; Stahl D; Catalona W J
Clinical and pathological features of hereditary prostate cancer.
The Journal of urology 1996;155(6):1841-3.
1996: Humphrey P A; Keetch D W; Smith D S; Shepherd D L; Catalona W J
Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening.
The Journal of urology 1996;155(3):816-20.
1995: Keetch D W; Rice J P; Suarez B K; Catalona W J
Familial aspects of prostate cancer: a case control study.
The Journal of urology 1995;154(6):2100-2.
1995: Keetch D W; Catalona W J
Prostatic transition zone biopsies in men with previous negative biopsies and persistently elevated serum prostate specific antigen values.
The Journal of urology 1995;154(5):1795-7.
1995: Catalona W J; Smith D S; Wolfert R L; Wang T J; Rittenhouse H G; Ratliff T L; Nadler R B
Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
JAMA : the journal of the American Medical Association 1995;274(15):1214-20.
1995: Dalkin B L; Ahmann F R; Kopp J B; Catalona W J; Ratliff T L; Hudson M A; Richie J P; Scardino P T; Flanigan R C; Dekernion J B
Derivation and application of upper limits for prostate specific antigen in men aged 50-74 years with no clinical evidence of prostatic carcinoma.
British journal of urology 1995;76(3):346-50.
1995: Nadler R B; Humphrey P A; Smith D S; Catalona W J; Ratliff T L
Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels.
The Journal of urology 1995;154(2 Pt 1):407-13.
1995: Keetch D W; Humphrey P; Stahl D; Smith D S; Catalona W J
Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate.
The Journal of urology 1995;154(2 Pt 1):347-51.
1995: Monk T G; Goodnough L T; Birkmeyer J D; Brecher M E; Catalona W J
Acute normovolemic hemodilution is a cost-effective alternative to preoperative autologous blood donation by patients undergoing radical retropubic prostatectomy.
Transfusion 1995;35(7):559-65.
1995: Smith D S; Catalona W J
Interexaminer variability of digital rectal examination in detecting prostate cancer.
Urology 1995;45(1):70-4.
1994: Catalona W J; Hudson M A; Scardino P T; Richie J P; Ahmann F R; Flanigan R C; deKernion J B; Ratliff T L; Kavoussi L R; Dalkin B L
Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.
The Journal of urology 1994;152(6 Pt 1):2037-42.
1994: Catalona W J; Richie J P; deKernion J B; Ahmann F R; Ratliff T L; Dalkin B L; Kavoussi L R; MacFarlane M T; Southwick P C
Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves.
The Journal of urology 1994;152(6 Pt 1):2031-6.
1994: Andriole G L; Smith D S; Rao G; Goodnough L; Catalona W J
Early complications of contemporary anatomical radical retropubic prostatectomy.
The Journal of urology 1994;152(5 Pt 2):1858-60.
1994: Catalona W J; Smith D S
5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer.
The Journal of urology 1994;152(5 Pt 2):1837-42.
1994: Smith D S; Catalona W J
The nature of prostate cancer detected through prostate specific antigen based screening.
The Journal of urology 1994;152(5 Pt 2):1732-6.
1994: Flanigan R C; Catalona W J; Richie J P; Ahmann F R; Hudson M A; Scardino P T; deKernion J B; Ratliff T L; Kavoussi L R; Dalkin B L
Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer.
The Journal of urology 1994;152(5 Pt 1):1506-9.
1994: Catalona W J
Management of cancer of the prostate.
The New England journal of medicine 1994;331(15):996-1004.
1994: Smith D S; Catalona W J
Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection.
The Journal of urology 1994;152(4):1163-7.
1994: Goodnough L M; Grishaber J E; Birkmeyer J D; Monk T G; Catalona W J
Efficacy and cost-effectiveness of autologous blood predeposit in patients undergoing radical prostatectomy procedures.
Urology 1994;44(2):226-31.
1994: Nadler R B; Catalona W J; Hudson M A; Ratliff T L
Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy.
The Journal of urology 1994;152(2 Pt 1):367-73.
1994: McCarthy J F; Catalona W J; Hudson M A
Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment.
The Journal of urology 1994;151(6):1575-8.
1994: Keetch D W; Catalona W J; Smith D S
Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values.
The Journal of urology 1994;151(6):1571-4.
1994: Goodnough L T; Grishaber J E; Monk T G; Catalona W J
Acute preoperative hemodilution in patients undergoing radical prostatectomy: a case study analysis of efficacy.
Anesthesia and analgesia 1994;78(5):932-7.
1994: Catalona W J; Richie J P; Ahmann F R; Hudson M A; Scardino P T; Flanigan R C; deKernion J B; Ratliff T L; Kavoussi L R; Dalkin B L
Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.
The Journal of urology 1994;151(5):1283-90.
1993: Andriole G L; Catalona W J
Using PSA to screen for prostate cancer. The Washington University experience.
The Urologic clinics of North America 1993;20(4):647-51.
1993: Keetch D W; Manley C B; Catalona W J
Transitional cell carcinoma of bladder in children and adolescents.
Urology 1993;42(4):447-9.
1993: Richie J P; Catalona W J; Ahmann F R; Hudson M A; Scardino P T; Flanigan R C; deKernion J B; Ratliff T L; Kavoussi L R; Dalkin B L
Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination.
Urology 1993;42(4):365-74.
1993: Catalona W J; Basler J W
Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy.
The Journal of urology 1993;150(3):905-7.
1993: Ratliff T L; Ritchey J K; Yuan J J; Andriole G L; Catalona W J
T-cell subsets required for intravesical BCG immunotherapy for bladder cancer.
The Journal of urology 1993;150(3):1018-23.
1993: Catalona W J; Smith D S; Ratliff T L; Basler J W
Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.
JAMA : the journal of the American Medical Association 1993;270(8):948-54.
1993: Keetch D W; Basler J W; Kavoussi L R; Catalona W J
Modification of Mitrofanoff principle for continent urinary diversion.
Urology 1993;41(6):507-10.
1993: Colberg J W; Smith D S; Catalona W J
Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml.
The Journal of urology 1993;149(3):507-9.
1992: Keetch D W; Klutke C G; Catalona W J
Late decompensation of neobladder.
The Journal of urology 1992;148(3):806-10.
1992: Petros J A; Catalona W J
Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer.
The Journal of urology 1992;147(6):1574-5.
1992: Bigg S W; Catalona W J
Prophylactic mini-dose heparin in patients undergoing radical retropubic prostatectomy. A prospective trial.
Urology 1992;39(4):309-13.
1992: Yuan J J; Coplen D E; Petros J A; Figenshau R S; Ratliff T L; Smith D S; Catalona W J
Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels.
The Journal of urology 1992;147(3 Pt 2):810-4.
1991: Kavoussi L R; Myers J A; Catalona W J
Effect of temporary occlusion of hypogastric arteries on blood loss during radical retropubic prostatectomy.
The Journal of urology 1991;146(2):362-5.
1991: Coplen D E; Andriole G L; Yuan J J; Catalona W J
The ability of systematic transrectal ultrasound guided biopsy to detect prostate cancer in men with the clinical diagnosis of benign prostatic hyperplasia.
The Journal of urology 1991;146(1):75-7.
1991: Petros J A; Catalona W J
Antegrade approach to radical retropubic prostatectomy in patients with difficult apical dissection.
The Journal of urology 1991;145(5):994-7.
1991: Catalona W J; Smith D S; Ratliff T L; Dodds K M; Coplen D E; Yuan J J; Petros J A; Andriole G L
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.
The New England journal of medicine 1991;324(17):1156-61.
1990: Hudson M A; Yuan J J; Catalona W J; Ratliff T L
Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
The Journal of urology 1990;144(6):1362-4.
1990: Bigg S W; Kavoussi L R; Catalona W J
Role of nerve-sparing radical prostatectomy for clinical stage B2 prostate cancer.
The Journal of urology 1990;144(6):1420-4.
1990: Catalona W J
Patient selection for, results of, and impact on tumor resection of potency-sparing radical prostatectomy.
The Urologic clinics of North America 1990;17(4):819-26.
1990: Coplen D E; Marcus M D; Myers J A; Ratliff T L; Catalona W J
Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
The Journal of urology 1990;144(3):652-7.
1990: Hudson M A; Ritchey J K; Catalona W J; Brown E J; Ratliff T L
Comparison of the fibronectin-binding ability and antitumor efficacy of various mycobacteria.
Cancer research 1990;50(13):3843-7.
1990: Hudson M A; Catalona W J
Effect of adjuvant radiation therapy on prostate specific antigen following radical prostatectomy.
The Journal of urology 1990;143(6):1174-7.
1990: Andriole G L; Yuan J J; Catalona W J
Cystotomy, temporary urinary diversion and bladder packing in the management of severe cyclophosphamide-induced hemorrhagic cystitis.
The Journal of urology 1990;143(5):1006-7.
1990: Catalona W J; Bigg S W
Nerve-sparing radical prostatectomy: evaluation of results after 250 patients.
The Journal of urology 1990;143(3):538-43; discussion 544.
1989: Hudson M A; Catalona W J; Ritchey J K; Aslanzadeh J; Brown E J; Ratliff T L
Choice of an optimal diluent for intravesical bacillus Calmette-Guerin administration.
The Journal of urology 1989;142(6):1438-41.
1989: Catalona W J; Whitmore W F
New staging systems for prostate cancer.
The Journal of urology 1989;142(5):1302-4.
1989: Andriole G L; Coplen D E; Mikkelsen D J; Catalona W J
Sonographic and pathological staging of patients with clinically localized prostate cancer.
The Journal of urology 1989;142(5):1259-61.
1989: Hudson M A; Bahnson R R; Catalona W J
Clinical use of prostate specific antigen in patients with prostate cancer.
The Journal of urology 1989;142(4):1011-7.
1988: Andriole G L; Kavoussi L R; Torrence R J; Lepor H; Catalona W J
Transrectal ultrasonography in the diagnosis and staging of carcinoma of the prostate.
The Journal of urology 1988;140(4):758-60.
1988: Catalona W J; Miller D R; Kavoussi L R
Intermediate-term survival results in clinically understaged prostate cancer patients following radical prostatectomy.
The Journal of urology 1988;140(3):540-3.
1988: Catalona W J
Modified inguinal lymphadenectomy for carcinoma of the penis with preservation of saphenous veins: technique and preliminary results.
The Journal of urology 1988;140(2):306-10.
1988: Bahnson R R; Catalona W J
Papaverine testing of impotent patients following nerve-sparing radical prostatectomy.
The Journal of urology 1988;139(4):773-4.
1987: Andriole G L; Catalona W J
Early diagnosis of prostate cancer.
The Urologic clinics of North America 1987;14(4):657-61.

Sign-in to see more